Acarix AB's (publ) ("Acarix") CEO, Søren Rysholt Christiansen, will be presenting at Vator Securities Unicorn Summit in Stockholm on 7 March 2017. Following its listing on Nasdaq First North Premier in Stockholm in December, Acarix will provide an update on upcoming activities for its CE-marked CADScor®System which provides non-invasive, radiation-free acoustic rule-out of Coronary Artery Disease (CAD) within minutes.
Vator Securities Unicorn Summit is a capital markets day with some of the most interesting and innovative companies in Sweden. Beyond company presentations, participants are offered a unique opportunity to network with industry peers and investors.
More information and registration will soon be available at www.vatorsecurities.se
Contacts:
Acarix A/S:
Søren Rysholt Christiansen, CEO
E-mail: dksrc@acarix.com
Phone: +45 2777 1112
Notes to editors:
Acarix , CADScor®System and cardiac sound measurement
Acarix A/S was established in 2009, and since 2010 investors SEED Capital (DK) and Sunstone Life Science Ventures (DK) have supported it towards market introduction. Acarix has attracted a highly-experienced management team who have held senior positions in international medical device companies - CEO Søren Rysholt Christiansen with ELOS Medtech, GN ReSound and Cook Medical.
Acarix's CADScor®System is based on engineering excellence in sound recording and signal processing. It has long been known that both cardiac contraction movement and turbulent flow can generate sound. Contraction related sounds are in lower frequency, whereas turbulent sounds in the streaming blood caused by partial obstruction (stenosis) in the coronary arteries are of higher frequencies. The detection of these murmurs is delicate, since the energy of the murmurs is very weak. Detecting and recording the coronary murmurs requires not only an advanced sensor but also means for proper attachment to the skin above the heart to optimize the recorded signal and to avoid external noise.
The Acarix CADScor®System has been designed to be an all-in-one system in the sense that the heart signal will be recorded, processed and displayed as a patient specific score, the CAD-score, on the device screen. The CADScor®System contains the necessary electronics to instruct professionals during use and guide the patient through the recording periods. The system also contains a docking station for daily qualification of the sensor. Further the system integrates with an adhesive patch for locking the CADScor® sensor to a fixed position above the heart during the recording.
The software embedded in The Acarix CADScor®System ensures that adequate recording conditions are controlled at every examination, whether performing your examinations in a quiet clinical settings or at busy GP clinics, at high altitudes (>95% coverage) or on the move.
The CADScor®System is CE Marked (by TÜV in 2015) and due for commercial launch in 2017.
See more at www.acarix.com
Attachments:
http://www.globenewswire.com/NewsRoom/AttachmentNg/1293e05c-75b3-4fb0-91de-65e07910633c
